Pınar GÜRSOY, BURCU ÇAKAR, Erhan GÖKMEN, BANU SARSIK KUMBARACI, Sait ŞEN, Erdal APAYDIN, A. Çağ ÇAL, AYŞE CANER, Serdar ÖZKÖK, Ayfer HAYDAROĞLU

Ege Üniversitesi Hastanesinde renal kanser hastalarının epidemiyolojisi ve genel sağ kalım özellikleri

Amaç: Ege Üniversitesi Hastanesinde 1992-Haziran 2018 arası kanser tanısı konan ve tedavisi yapılan renal kanser tanılı hastaların genel özellikleri, tedavi modaliteleri ve sağ kalım sürelerinin tanımlanması amaçlanmıştır. Gereç ve Yöntem: Ege Üniversitesi Kanserle Savaş Araştırma ve Uygulama Merkezi tarafından toplanan renal kanser verileri CANREG özel bilgisayar programına kayıt edilmiş, DSÖ ve SEER sistemleri temelinde gruplanarak analizler yapılmıştır. İstatistik analizlerde Fisher’s Exact Test,KaplanMeier sağ kalım analizleri uygulanmıştır. Sağ kalım analizinde Log Rank (Mantel-Cox), Breslow (Generalized Wilcoxon) ve Tarone-Ware istatistikleri kullanılmıştır. İstatistik analizlerde p

Epidemiological and overall survival characteristics of kidney cancer patients in Ege University Hospital database

Aim: The purpose of this study was to describe the general characteristics, treatment modalities and overall survival times of kidney cancer patients that diagnosed and treated in between 1992 –and June 2018 at Ege University Hospital. Materials and Methods: Ege University Cancer Control, Research and Application Center registered the collected kidney cancer data in CANREG which is a special computer program for grouping and analyzing the data in WHO and SEER based systems. Fisher’s Exact Test Kaplan Meier survival analyzing technique was used in statistical analysis. Log Rank(Mantel-Cox), Breslow(Generalized Wilcoxon) and Tarone-Ware statistical techniques were used in survival analysis. P

PDF

___

1.SEER Stat Fact Sheets: Kidney and Renal Pelvis. http://seer.cancer.gov/statfacts/html/kidrp.html .

2.Störkel S,van den Berg E. Morphological classification of renal cancer. World J Urol. 1995;13(3):153-8.

3.Israel GM, Bosniak MA. How I do it: evaluating renal masses. Radiology, 236 (2), 441-50.

4.Johnson CD, Dunnick NR, Cohan RH, Illescas FF. Renal adenocarcinoma: CT staging of 100 tumors. AJR Am J Roentgenol, 148 (1), 59-63.

5.Koga S, Tsuda S, Nishikido M et al. The diagnostic value of bone scan in patients with renal cell carcinoma. J Urol, 166 (6), 2126-8.

6. Ramdave S, Thomas GW, Berlangieri SU et al.Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma. J Urol. 2001 Sep;166(3):825-30.

7.Novara G, Martignoni G, Artibani W, Ficarra V. Grading systems in renal cell carcinoma. J Urol. 2007 Feb;177(2):430-6.

8. Cheville JC, Lohse CM, Zincke H et al. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol. 2003 May;27(5):612-24.

9. Kassouf W, Sanchez-Ortiz R, Tamboli P et al. Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology. . J Urol. 2007 Nov;178(5):1896-900. Epub 2007 Sep 17.

10. Motzer RJ, Hutson TE, Tomczak P et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009 Aug 1;27(22):3584-90. doi: 10.1200/JCO.2008.20.1293. Epub 2009 Jun 1.

11.Rini BI, Halabi S, Rosenberg JE et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. . J Clin Oncol. 2010 May 1;28(13):2137-43. doi: 10.1200/JCO.2009.26.5561. Epub 2010 Apr 5.